Skip to main content

Advertisement

SpringerLink
Log in

Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Pituitary tumor-transforming gene 1 (PTTG1) has been identified as an oncogene and is overexpressed in many tumor types. However, the role of PTTG1 in glioblastoma (GBM) has not been well characterized, especially in relation to angiogenesis, migration, and invasion. In the present study, our results showed that the expression of PTTG1 was significantly higher in patients with GBM. Bioinformatic analysis showed that angiogenesis and the cell migration-related process were increased in patients with high PTTG1 expression levels; meanwhile, PTTG1 was positively correlated with marker genes of angiogenesis, migration and the evasion of apoptosis. In vitro assays showed that PTTG1 knockdown dramatically suppressed angiogenesis, migration and invasion, and increased the apoptosis of GBM cells. Moreover, our results also showed that silencing PTTG1 suppressed the activity of the TGF-β/PI3K-AKT-mTOR pathway, which induced tumor deterioration in multiple organs. Overall, our findings indicate that PTTG1 is a glioma malignant factor that promotes angiogenesis, migration, invasion, and the evasion of apoptosis, and these roles may be related to the TGF-β/PI3K-AKT-mTOR pathway. Thus, the targeted inhibition of PTTG1 might be a novel therapeutic strategy and a potential diagnostic biomarker for GBM-targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data availability

All data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet (London, England). 2019;393:678–88.

    Article  CAS  Google Scholar 

  2. Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018;560:243–7.

    Article  CAS  Google Scholar 

  3. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–8.

    Article  CAS  Google Scholar 

  4. Zeng W, Liu P, Pan W, Singh SR, Wei Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356:263–7.

    Article  CAS  Google Scholar 

  5. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3:489–501.

    Article  CAS  Google Scholar 

  6. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet (London, England). 2000;355:716–9.

    Article  CAS  Google Scholar 

  7. Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol. 2009;43:179–85.

    Article  CAS  Google Scholar 

  8. Lin X, Yang Y, Guo Y, et al. PTTG1 is involved in TNF-alpha-related hepatocellular carcinoma via the induction of c-myc. Cancer Med. 2019;8:5702–15.

    Article  CAS  Google Scholar 

  9. Hu ZG, Zheng CW, Su HZ, et al. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma. J Cell Biochem. 2019;120:9964–78.

    Article  CAS  Google Scholar 

  10. Su X, Chen J, Ni L, et al. Inhibition of PTTG1 expression by microRNA suppresses proliferation and induces apoptosis of malignant glioma cells. Oncol Lett. 2016;12:3463–71.

    Article  CAS  Google Scholar 

  11. Fujii T, Nomoto S, Koshikawa K, et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology (Baltimore, MD). 2006;43:1267–75.

    Article  CAS  Google Scholar 

  12. Xiang W, Wu X, Huang C, et al. PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth. Oncotarget. 2017;8:664–78.

    Article  Google Scholar 

  13. Yoon CH, Kim MJ, Lee H, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012;287:19516–27.

    Article  CAS  Google Scholar 

  14. Zhi T, Jiang K, Xu X, et al. MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1. Am J Transl Res. 2017;9:4872–87.

    PubMed  PubMed Central  CAS  Google Scholar 

  15. Zhi T, Jiang K, Xu X, et al. ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. Neuro-Oncology. 2019;21:462–73.

    Article  CAS  Google Scholar 

  16. Cui LLT, Xu L, Wang G, Lin J, Feng S, Cao Y, Cao Y, Song Z, Jin X. The effect of down-regulated gene PTTG1 on proliferation, apoptosis, migration and invasion of human glioma cell SHG44. China Oncol. 2019;29:338–44.

    Google Scholar 

  17. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep. 2006;15:1569–74.

    PubMed  CAS  Google Scholar 

  18. Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M. Epidemiology and molecular pathology of glioma. Nature clinical practice. Neurology. 2006: 2: 494–503; quiz 491 p following 516.

  19. Wang X, Chen D, Gao J, et al. Centromere protein U expression promotes non-small-cell lung cancer cell proliferation through FOXM1 and predicts poor survival. Cancer Manag Res. 2018;10:6971–84.

    Article  CAS  Google Scholar 

  20. Hamid T, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer. 2005;4:3.

    Article  CAS  Google Scholar 

  21. Huang JL, Cao SW, Ou QS, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer. 2018;17:93.

    Article  CAS  Google Scholar 

  22. Ren Q, Jin B. The clinical value and biological function of PTTG1 in colorectal cancer. Biomed Pharmacother. 2017;89:108–15.

    Article  CAS  Google Scholar 

  23. Shono T, Mizoguchi M, Sasaki T. Latest treatment strategies for malignant gliomas. Fukuoka Igaku Zasshi. 2007;98:333–6.

    PubMed  Google Scholar 

  24. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.

    Article  CAS  Google Scholar 

  25. Zhang G, Zhao Q, Yu S, Lin R, Yi X. Pttg1 inhibits TGFbeta signaling in breast cancer cells to promote their growth. Tumour Biol. 2015;36:199–203.

    Article  CAS  Google Scholar 

  26. Demin DE, Bogolyubova AV, Zlenko DV, et al. The novel short isoform of securin stimulates the expression of cyclin D3 and angiogenesis factors VEGFA and FGF2, but does not affect the expression of MYC transcription factor. Mol Biol. 2018;52:508–18.

    Article  CAS  Google Scholar 

  27. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updates. 2008;11:32–50.

    Article  CAS  Google Scholar 

  28. Chen XF, Zhang HJ, Wang HB, et al. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 2012;39:3549–56.

    Article  CAS  Google Scholar 

  29. Dong F, Liu T, Jin H, Wang W. Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-beta1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways. Can J Physiol Pharmacol. 2018;96:1–7.

    Article  CAS  Google Scholar 

  30. Jiang X, Zhang Z, Song C, et al. Glaucocalyxin A reverses EMT and TGF-beta1-induced EMT by inhibiting TGF-beta1/Smad2/3 signaling pathway in osteosarcoma. Chem Biol Interact. 2019;307:158–66.

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported by Grants from the Fundamental Research Funds for the Central Universities (No. 20720180042), the Health Science Research Personnel Training Program of Fujian Province (2016-CXB-12), the Natural Science Foundation of Fujian, China (No. 2016D019).

Author information

Author notes

  1. Lishan Cui and Tong Ren contributed equally to this work.

Authors and Affiliations

  1. Xiang’an Branch, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361005, China

    Lishan Cui, Haitao Zhao, Shuide Chen & Mingcheng Zheng

  2. Xiamen Fifth Hospital, Xiamen, 361005, China

    Lishan Cui, Haitao Zhao, Shuide Chen & Mingcheng Zheng

  3. Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China

    Tong Ren

  4. School of Pharmacy, Xiamen University, Xiamen, China

    Xuemin Gao

  5. School of Medicine, Xiamen University, Xiang’an District, Xiamen, 361102, China

    Dingrui Feng, Lichao Yang, Xin Jin & Rengong Zhuo

Authors
  1. Lishan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haitao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuide Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingcheng Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xuemin Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dingrui Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lichao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xin Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rengong Zhuo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YLC and JX designed the experiments and drafted the manuscript. CLS, RT, SZH, GXM and FDR performed the study, and ZHT, CSD, ZMS performed the statistical analysis. ZRG revised the manuscript. All authors have read and approved the final manuscript.

Corresponding authors

Correspondence to Lichao Yang, Xin Jin or Rengong Zhuo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 393 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, L., Ren, T., Zhao, H. et al. Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells. Med Oncol 37, 73 (2020). https://doi.org/10.1007/s12032-020-01398-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-020-01398-2

Keywords

Search

Navigation